Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Roche Holding AG stock logo
RHHBY
Roche
$54.52
-1.7%		$52.71
$39.39
▼
$60.85
$347.32B0.491.95 million shs1.48 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.10
-1.7%		$17.08
$14.68
▼
$25.32
$1.91B0.233.19 million shs1.56 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Roche Holding AG stock logo
RHHBY
Roche
0.00%-4.79%+5.97%+6.71%+41.28%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+7.87%+5.05%+3.13%-11.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Roche Holding AG stock logo
RHHBY
Roche
$54.52
-1.7%		$52.71
$39.39
▼
$60.85
$347.32B0.491.95 million shs1.48 million shs
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$18.10
-1.7%		$17.08
$14.68
▼
$25.32
$1.91B0.233.19 million shs1.56 million shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Roche Holding AG stock logo
RHHBY
Roche
0.00%-4.79%+5.97%+6.71%+41.28%
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.00%+7.87%+5.05%+3.13%-11.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Roche Holding AG stock logo
RHHBY
Roche
2.36
Hold$60.0010.05% Upside
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
2.20
Hold$25.0638.45% Upside

Current Analyst Ratings Breakdown

Latest SRPT and RHHBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/7/2026
Roche Holding AG stock logo
RHHBY
Roche
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$63.00
8/5/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
7/28/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/20/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
7/14/2026
Roche Holding AG stock logo
RHHBY
Roche
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/9/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetNeutral$23.00 ➝ $20.00
7/9/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$27.00
7/7/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/6/2026
Roche Holding AG stock logo
RHHBY
Roche
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
6/29/2026
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D+) ➝ Sell (D)
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Roche Holding AG stock logo
RHHBY
Roche
$76.45B4.54$3.60 per share15.14$7.18 per share7.59
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
$1.97B0.97N/AN/A$14.46 per share1.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Roche Holding AG stock logo
RHHBY
Roche
$15.55BN/AN/A16.524.01N/AN/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
-$713.41M-$2.90N/A9.840.24-13.48%-1.60%-0.66%11/4/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Roche Holding AG stock logo
RHHBY
Roche
$0.971.78%N/AN/AN/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Roche Holding AG stock logo
RHHBY
Roche
0.72
1.38
1.12
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
0.55
4.42
2.62

Institutional Ownership

CompanyInstitutional Ownership
Roche Holding AG stock logo
RHHBY
Roche
N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
86.68%

Insider Ownership

CompanyInsider Ownership
Roche Holding AG stock logo
RHHBY
Roche
N/A
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
6.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,2496.37 billionN/ANot Optionable
Sarepta Therapeutics, Inc. stock logo
SRPT
Sarepta Therapeutics
1,372105.63 million98.34 millionOptionable

Recent News About These Companies

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research
August 14 at 5:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sarepta-therapeutics-nasdaqsrpt-upgraded-to-hold-at-zacks-research-2026-08-14/
Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT
August 13 at 3:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-increases-stock-position-in-sarepta-therapeutics-inc-srpt-2026-08-13/
Sarepta (SRPT) Q2 2026 Earnings Call Transcript
August 12, 2026  |  fool.comhttps://www.fool.com/earnings/call-transcripts/2026/08/12/sarepta-srpt-q2-2026-earnings-call-transcript/
Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT
August 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-makes-new-816-million-investment-in-sarepta-therapeutics-inc-srpt-2026-08-12/
Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-121412-shares-of-sarepta-therapeutics-inc-srpt-2026-08-11/
Barclays Reaffirms Their Hold Rating on Sarepta Therapeutics (SRPT)
August 10, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SRPT-Q/pressreleases/3733594/barclays-reaffirms-their-hold-rating-on-sarepta-therapeutics-srpt/
Stock Traders Buy Large Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT)
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949301
Wedbush Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
August 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SRPT/pressreleases/3716511/wedbush-keeps-their-buy-rating-on-sarepta-therapeutics-srpt/
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Hold at Wall Street Zen
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947506
Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sarepta-therapeutics-nasdaqsrpt-rating-lowered-to-hold-at-wall-street-zen-2026-08-08/
Traders Purchase Large Volume of Call Options on Sarepta Therapeutics (NASDAQ:SRPT)
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/traders-purchase-large-volume-of-call-options-on-sarepta-therapeutics-nasdaqsrpt-2026-08-07/
Sarepta Therapeutics Balances Profit Gains With Revenue Strain
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/sarepta-therapeutics-balances-profit-gains-with-revenue-strain?utm_source=marketbeat.com&utm_medium=referral
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sareptas-q2-earnings-sales-beat-180500321.html
Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2970349/sarepta-s-q2-earnings-sales-beat-estimates-26-outlook-updated?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970349
Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sarepta-faces-competitive-pressures-despite-175958762.html
Sarepta Therapeutics, Inc. Q2 2026 Earnings Call Summary
August 6, 2026  |  app.moby.coA
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ...
August 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/sarepta-therapeutics-inc-srpt-q2-051140771.html
Empowered Funds LLC Has $2.48 Million Stake in Sarepta Therapeutics, Inc. $SRPT
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-has-248-million-stake-in-sarepta-therapeutics-inc-srpt-2026-08-06/
Sarepta Therapeutics Q2 Earnings Call Highlights
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/sarepta-therapeutics-q2-earnings-call-highlights-2026-08-06/
Sarepta Therapeutics, Inc. (SRPT) Q2 2026 Earnings Call Transcript
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931360-sarepta-therapeutics-inc-srpt-q2-2026-earnings-call-transcript
Sarepta Therapeutics, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4931423-sarepta-therapeutics-inc-2026-q2-results-earnings-call-presentation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Roche stock logo

Roche OTCMKTS:RHHBY

$54.52 -0.97 (-1.75%)
As of 08/14/2026 04:00 PM Eastern

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.

Sarepta Therapeutics stock logo

Sarepta Therapeutics NASDAQ:SRPT

$18.10 -0.32 (-1.74%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$17.70 -0.40 (-2.23%)
As of 08/14/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas